CureVac N.V (CVAC): Price and Financial Metrics

CureVac N.V (CVAC): $5.52

0.10 (+1.85%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

F

Add CVAC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#163 of 346

in industry

CVAC Price/Volume Stats

Current price $5.52 52-week high $12.79
Prev. close $5.42 52-week low $4.95
Day low $5.41 Volume 196,283
Day high $5.60 Avg. volume 710,294
50-day MA $5.69 Dividend yield N/A
200-day MA $7.90 Market Cap 1.24B

CVAC Stock Price Chart Interactive Chart >


CureVac N.V (CVAC) Company Bio


CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.(Source:Wikipedia)


CVAC Latest News Stream


Event/Time News Detail
Loading, please wait...

CVAC Latest Social Stream


Loading social stream, please wait...

View Full CVAC Social Stream

Latest CVAC News From Around the Web

Below are the latest news stories about CUREVAC NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.

Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 191.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 21, 2023

CureVac N.V. (NASDAQ:CVAC) Q3 2023 Earnings Call Transcript

CureVac N.V. (NASDAQ:CVAC) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Greetings and welcome to the CureVac Financial Results for Third Quarter and First Nine Months of 2023 Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, […]

Yahoo | November 15, 2023

CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 37%, while individual investors hold 31%

Key Insights The considerable ownership by private equity firms in CureVac indicates that they collectively have a...

Yahoo | November 15, 2023

Q3 2023 CureVac NV Earnings Call

Q3 2023 CureVac NV Earnings Call

Yahoo | November 15, 2023

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateEnrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early ...

Yahoo | November 14, 2023

Read More 'CVAC' Stories Here

CVAC Price Returns

1-mo 0.73%
3-mo -37.06%
6-mo -43.15%
1-year -26.01%
3-year -94.80%
5-year N/A
YTD -8.46%
2022 -82.42%
2021 -57.68%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!